Summary
Amantadine is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. ClinicalTrials.gov lists 2 registered trials linking Amantadine to Long COVID: 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT06055244, sponsored by Ohio State University). It plans or enrolled 64 participants. Registration activity spans 2023 to 2025. The literature layer holds 1 publication for this pair: 1 clinical trial publication. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
Long COVID / PASC is tracked on the OSMF post-viral programme alongside ME/CFS, Long COVID, POTS and MCAS. Across the programme, 423 candidate agents are logged for Long COVID, most of them preliminary; this page isolates the record for one of them.
Evidence table
| Evidence tier | C · Preliminary |
|---|---|
| Evidence score | 12.0 (trials 5.0, literature 2.0, tier 5, approved bonus 0.0) |
| Registered trials | 2 total: 0 recruiting, 0 active / not yet recruiting, 1 completed, 1 other |
| Linked publications | 1 (1 clinical trial publication) |
| Agent type | Other (Other / Unclassified) |
| Development stage (any indication) | Investigational |
| Mechanism / class | Neurological / Autonomic |
| Data sources | OSMF therapeutic agent database, ClinicalTrials.gov, PubMed |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT06055244 | Amantadine Therapy for Cognitive Impairment in Long COVID Ohio State University · 2023 | completed | Phase 2 | 64 |
| NCT06234462 | A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid University of Texas Southwestern Medical Center · 2025 | withdrawn | Phase 2 | — |
Published literature
- Clinical trial publication (PubMed validation search) PubMed record PMID 38228731
Mechanism and notes
Recorded mechanism or class: Neurological / Autonomic.
Clinical notes: Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.
Safety: Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing in studies: See linked studies/trials for reported doses and durations; typical protocols vary widely.
Frequently asked questions
Is Amantadine approved for Long COVID?
Amantadine is tracked by OSMF as an investigational option for Long COVID; no regulator has approved it for this indication, and most post-viral conditions have no approved disease-modifying therapy at all. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Amantadine in clinical trials for Long COVID?
ClinicalTrials.gov lists 2 registered trials linking Amantadine to Long COVID: 1 has completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 2 (NCT06055244, sponsored by Ohio State University). It plans or enrolled 64 participants. Registration activity spans 2023 to 2025.
What does the evidence show for Amantadine in Long COVID?
Amantadine has 1 completed trial and 1 linked publication for Long COVID. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is C (Preliminary), taken from the OSMF therapeutic agent database, which grades agents by the volume and design of condition-specific evidence rather than by effect size.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-10-07. Page built 2026-10-07.